Chapter 1. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET- Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET- Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– By Technology

6.1. PCR

6.2. NGS

6.3. IHC

6.4. ISH/FISH

Chapter 7. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– By End-User

7.1. Hospitals

7.2. Pathology / Diagnostic

7.3. Laboratory

Chapter 8. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET– By Region

8.1. North America

8.2. Europe

8.3. The Asia Pacific

8.4. Latin America

8.5. Middle-East and Africa

Chapter 9. COMPANION DIAGNOSTIC TESTS IN ONCOLOGY MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

9.1. Company 1

9.2. Company 2

9.3. Company 3

9.4. Company 4

9.5. Company 5

9.6. Company 6

9.7. Company 7

9.8. Company 8

9.9. Company 9

9.10. Company 10